Cancer Type: Head & Neck
Study Type: Treatment
NCT#: NCT03383094
Phase: Phase II
Principal Investigator: Caudell, Jimmy
Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial)
This study is a prospective, multi-institutional, open-label, randomized phase II trial that will evaluate the efficacy of concurrent and adjuvant pembrolizumab with radiation therapy (RT) versus RT plus cisplatin in intermediate/high-riskp16-positive locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
Primary Objective(s): Objective: To determine whether RT with concurrent and adjuvant anti-PD1 therapy (pembrolizumab) is feasible in patients with intermediate/high risk p16+ locoregionally advanced head/neck cancer Phase II Objective: To test the hypothesis that pembrolizumab improves progression free survival (PFS) in this population compared to standard of care (RT plus cisplatin) Secondary Objectives Objective 1: To quantify acute and late toxicity, overall survival, radiographic response (at 4-month FDG-PET-CT), locoregional failure, distant metastasis, immune correlates, and competing mortality for RT/pembrolizumab compared to RT plus cisplatin in this population. Objective 2: To examine the relationships between age, baseline vulnerability score (as measured by the G-8 tool), and baseline competing event score (GCE-ω) and select outcomes including acute and late toxicity, locoregional control, distant metastasis, and overall survival. Exploratory Objective(s) & Hypothesis(es) Objective: To compare the outcomes with RT/pembrolizumab in patients with tumors as a function of PD-L1 expression.
Chemotherapy (NOS); Immunotherapy; Radiotherapy
Pembrolizumab (Keytruda); cisplatin ()
Inclusion Criteria:
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday